About Oncolytics Biotech (TSE:ONC)
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolTSE:ONC
CUSIPN/A
Phone+1-403-6707380
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-91.52%
Return on Assets-74.32%
Miscellaneous
EmployeesN/A
Outstanding Shares142,325,000
Oncolytics Biotech (TSE:ONC) Frequently Asked Questions
What is Oncolytics Biotech's stock symbol?
Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."
How were Oncolytics Biotech's earnings last quarter?
When is Oncolytics Biotech's next earnings date?
What price target have analysts set for ONC?
1 brokers have issued 1-year price targets for Oncolytics Biotech's shares. Their predictions range from C$3.25 to C$3.25. On average, they expect Oncolytics Biotech's share price to reach C$3.25 in the next year. View Analyst Ratings for Oncolytics Biotech.
Who are some of Oncolytics Biotech's key competitors?
Some companies that are related to Oncolytics Biotech include Btb Reit (BTB.UN), Tecsys (TCS), Asanko Gold (AKG), NAPEC (NPC), Stuart Olson (SOX), High Arctic Energy Services (HWO), GDI Integrated Facility Services (GDI), NewCastle Gold (NCA), Yellow Pages (Y), Alexco Resource (AXR), Freshii (FRII), North American Energy Partners (NOA), Copper Mountain Mining (CMMC), Delphi Energy (DEE), Conifex Timber (CFF), Automotive Properties Real Est Invt TR (APR.UN), Nautilus Minerals (NUS) and Xtreme Drilling (XDC).
Who are Oncolytics Biotech's key executives?
Oncolytics Biotech's management team includes the folowing people:
- Dr. Matthew C. Coffey, Pres, CEO & Director
- Mr. Kirk J. Look CA, Chief Financial Officer
- Dr. Andres A. Gutierrez M.D., Ph.D., Chief Medical Officer (Age 57)
- Mr. Michael Moore, VP of Investor Relations & Corp. Communications
- Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 51)
Has Oncolytics Biotech been receiving favorable news coverage?
Media coverage about ONC stock has been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Oncolytics Biotech earned a daily sentiment score of 0.17 on Accern's scale. They also gave media stories about the company an impact score of 46.17 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Oncolytics Biotech?
Shares of ONC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Oncolytics Biotech's stock price today?
One share of ONC stock can currently be purchased for approximately C$0.70.
How big of a company is Oncolytics Biotech?
Oncolytics Biotech has a market capitalization of C$111.15 million.
How can I contact Oncolytics Biotech?
Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The company can be reached via phone at +1-403-6707380.
MarketBeat Community Rating for Oncolytics Biotech (ONC)
MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe ONC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Oncolytics Biotech (TSE:ONC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Oncolytics Biotech in the last 12 months. Their average twelve-month price target is C$3.25, suggesting that the stock has a possible upside of 364.29%. The high price target for ONC is C$3.25 and the low price target for ONC is C$3.25. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Buy | Buy | Buy |
| Consensus Rating Score: | 2.00 | 2.67 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | C$3.25 | C$2.08 | C$1.50 | C$1.50 |
| Price Target Upside: | 364.29% upside | 206.37% upside | 50.00% upside | 50.00% upside |
Oncolytics Biotech (TSE:ONC) Consensus Price Target History
Oncolytics Biotech (TSE:ONC) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Oncolytics Biotech (TSE:ONC) Earnings History and Estimates Chart
Oncolytics Biotech (TSE ONC) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/4/2018 | | | | | | | | |
| 3/9/2018 | Q4 2017 | | C($0.03) | | | View | N/A |  |
| 11/8/2017 | Q3 2017 | C($0.03) | C($0.02) | | | View | N/A | |
| 8/3/2017 | Q2 2017 | C($0.03) | C($0.03) | | | View | N/A | |
| 5/5/2017 | Q1 2017 | C($0.03) | C($0.03) | | | View | N/A | |
| 3/10/2017 | Q4 2016 | | C($0.04) | | | View | N/A | |
| 11/3/2016 | Q3 2016 | | C($0.03) | | | View | N/A | |
| 8/4/2016 | Q2 2016 | | C($0.02) | | | View | N/A | |
| 5/6/2016 | Q1 2016 | | C($0.03) | | | View | N/A | |
| 3/11/2016 | Q4 2015 | | C($0.03) | | | View | N/A | |
| 11/5/2015 | Q3 2015 | | C($0.02) | | | View | N/A | |
| 8/6/2015 | Q2 2015 | | C($0.03) | | | View | N/A | |
| 5/7/2015 | Q1 2015 | | C($0.04) | | | View | N/A | |
| 3/13/2015 | Q4 2014 | | C($0.04) | | | View | N/A | |
| 11/6/2014 | Q3 2014 | | C($0.05) | | | View | N/A | |
| 8/7/2014 | Q2 14 | C($0.07) | C($0.05) | | | View | N/A | |
| 5/8/2014 | Q1 2014 | | C($0.06) | | | View | N/A | |
| 3/13/2014 | Q4 2013 | | C($0.07) | | | View | N/A | |
| 11/7/2013 | Q3 13 | C($0.07) | C($0.07) | | | View | N/A | |
| 8/1/2013 | Q2 2013 | | C($0.06) | | | View | N/A | |
| 5/9/2013 | Q1 2013 | C($0.11) | C($0.08) | | | View | N/A | |
| 3/14/2013 | Q4 2012 | C($0.10) | C($0.11) | | | View | N/A | |
| 11/8/2012 | Q3 2012 | C($0.13) | C($0.12) | | | View | N/A | |
| 8/2/2012 | Q2 2012 | C($0.12) | C($0.13) | | | View | N/A | |
| 5/10/2012 | Q1 2012 | C($0.10) | C($0.11) | | | View | N/A | |
| 3/15/2012 | Q4 2011 | C($0.10) | C($0.16) | | | View | N/A | |
| 11/10/2011 | Q3 2011 | C($0.07) | C($0.09) | | | View | N/A | |
| 7/28/2011 | Q2 2011 | C($0.07) | C($0.09) | | | View | N/A | |
| 5/12/2011 | Q1 2011 | C($0.07) | C($0.06) | | | View | N/A | |
| 3/17/2011 | Q4 2010 | C($0.06) | C($0.12) | | | View | N/A | |
| 11/10/2010 | Q3 2010 | C($0.08) | C($0.07) | | | View | N/A | |
| 7/29/2010 | Q2 2010 | C($0.07) | C($0.07) | | | View | N/A | |
| 5/12/2010 | Q1 2010 | C($0.08) | C$0.07 | | | View | N/A | |
| 11/5/2009 | Q3 2009 | C($0.09) | C($0.05) | | | View | N/A | |
| 7/29/2009 | Q2 2009 | C($0.09) | C($0.09) | | | View | N/A | |
| 5/5/2009 | Q1 2009 | C($0.11) | C($0.09) | | | View | N/A | |
| 11/4/2008 | Q3 2008 | | C$0.10 | | | View | N/A | |
| 7/29/2008 | Q2 2008 | | C($0.13) | | | View | N/A | |
| 4/30/2008 | Q1 2008 | | C($0.08) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Oncolytics Biotech (TSE:ONC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Oncolytics Biotech (TSE ONC) Insider Trading and Institutional Ownership History
Oncolytics Biotech (TSE ONC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/26/2015 | Angela Frances Holtham | Director | Buy | 5,000 | C$0.89 | C$4,450.00 | | |
| 5/12/2015 | Wayne Pisano | Director | Buy | 20,000 | C$0.76 | C$15,150.00 | | |
(Data available from 1/1/2013 forward)
Oncolytics Biotech (TSE ONC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | BRIEF-Oncolytics Biotech Chief Medical Officer To Leave Effective April 23
www.reuters.com - April 18 at 10:10 AM |
 | Oncolytics Biotech(R) Announces Management Change
finance.yahoo.com - April 17 at 4:10 PM |
| ONCYF: A Whirlwind 2017 Readies Spate of New Trials
finance.yahoo.com - March 26 at 10:42 AM |
 | Oncolytics Biotech Inc. (ONC) to Post FY2018 Earnings of ($0.12) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - March 15 at 8:44 AM |
| BRIEF-Oncolytics Biotech Inc Announces 2017 Year-End Results
www.reuters.com - March 9 at 11:17 AM |
 | M&A, Innovation & New Drugs to Drive Pharma Stocks
www.zacks.com - March 8 at 4:36 PM |
 | Merck Turns to Tumor-Killing Viruses to Boost Immune Cancer ... - Bloomberg
www.bloomberg.com - March 2 at 4:28 PM |
| Oncolytics Biotech (ONC) Price Target Raised to C$3.25
www.americanbankingnews.com - February 26 at 2:40 PM |
| BRIEF-Oncolys BioPharma invests in US Biotech Venture Specialized in Development of Novel Oncolytic Adenovirus
www.reuters.com - February 16 at 4:04 PM |
| Oncolytics Biotech(R) to Present at the RBC Capital Markets 2018 Healthcare Conference
finance.yahoo.com - February 14 at 8:45 AM |
| Research Reports on Oncolytics Biotech, Aurinia Pharma, Immunovaccine, and IntelliPharmaCeutics
finance.yahoo.com - February 12 at 8:42 AM |
| Oncolytics Biotech(R) to Host Conference Call Outlining the Treatment Paradigm of Metastatic Breast Cancer Subtypes and Provide Topline Information on its Phase 3 Registration Study with REOLYSIN(R)
finance.yahoo.com - February 1 at 8:47 AM |
| Oncolytics Biotech® Inc. Announces Plans to Apply to List Common Shares on the NASDAQ Capital Market
finance.yahoo.com - January 29 at 8:48 AM |
| Oncolytics Biotech(R) Named to the 2018 OTCQX Best 50
finance.yahoo.com - January 25 at 8:41 AM |
| BRIEF-Oncolytics Biotech Receives Final Advice Letter From European Medicines Agency For Reolysin In Metastatic Breast Cancer
www.reuters.com - December 5 at 11:55 AM |
 | Oncolytics Biotech® Establishes Scientific Advisory Board Focused ... - PR Newswire (press release)
www.prnewswire.com - November 30 at 10:50 AM |
 | Oncolytics Biotech (ONCYF) Updates On Clinical Data & Development Plan - Slideshow
seekingalpha.com - November 21 at 9:00 AM |
| BRIEF-Oncolytics Biotech Inc reports qtrly share of $0.02
www.reuters.com - November 9 at 10:06 AM |
| Oncolytics Biotech® Appoints Deborah Brown to Board of Directors - PR Newswire (press release)
www.prnewswire.com - November 4 at 8:31 AM |
| Sorrento Therapeutics: Buy, Sell Or Hold After Its Big Rally?
seekingalpha.com - October 14 at 6:26 AM |
 | Form 6-K ONCOLYTICS BIOTECH INC For: Oct 11 - StreetInsider.com
www.streetinsider.com - October 13 at 7:44 AM |
| Oncolytics’ (ONCYF) End of Phase II Meeting
finance.yahoo.com - September 22 at 7:21 AM |
| BRIEF-Oncolytics announces successful end-of-Phase 2 meeting with FDA for reolysin
www.reuters.com - September 19 at 6:11 AM |
| BRIEF-Oncolytics Biotech announces first patient treated in Muk Eleven study
www.reuters.com - September 14 at 8:46 AM |
| Oncolytics Biotech® Announces the Presentation of REOLYSIN ... - PR Newswire (press release)
www.prnewswire.com - September 12 at 8:40 AM |
| Oncolytics’ (ONCYF) Second Quarter Results
finance.yahoo.com - August 15 at 5:44 AM |
| FY2017 EPS Estimates for Oncolytics Biotech Inc. (ONC) Decreased by Analyst
www.americanbankingnews.com - August 10 at 10:42 AM |
| Oncolytics Biotech® Inc. Announces 2017 Second Quarter Results
finance.yahoo.com - August 4 at 6:40 AM |
| Oncolytics reports 2Q loss
finance.yahoo.com - August 4 at 6:40 AM |
| Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference - PR Newswire (press release)
www.prnewswire.com - August 2 at 6:37 AM |
| BRIEF-Oncolytics Biotech granted end-of-phase 2 meeting with FDA
www.reuters.com - July 27 at 6:04 AM |
| Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress
finance.yahoo.com - July 27 at 6:04 AM |
| Oncolytics (ONCYF) Raises CAD$11 Million
finance.yahoo.com - July 6 at 7:41 AM |
| Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (US) Inc. - PR Newswire (press release)
www.prnewswire.com - July 1 at 6:22 AM |
| Oncolytics Biotech® Inc. Opens US Based Office in San Diego - PR Newswire (press release)
www.prnewswire.com - June 29 at 12:36 AM |
| Oncolytics Biotech® Prices Public Offering of Units
www.prnewswire.com - May 24 at 7:16 PM |
 | Oncolytics Biotech Prices Public Offering of Units
www.marketwatch.com - May 24 at 7:16 PM |
| BRIEF-Oncolytics Biotech prices public offering of units
www.reuters.com - May 24 at 7:15 PM |
 | FDA Grants Fast Track Status to Oncolytics' Reolysin for Breast Cancer
www.baystreet.ca - May 8 at 12:09 PM |
| BRIEF-Oncolytics Biotech Inc announces FDA fast track designation for Reolysin
www.reuters.com - May 8 at 12:09 PM |
| Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders - PR Newswire (press release)
www.prnewswire.com - May 5 at 7:20 PM |
| Oncolytics Biotech® Inc. Announces 2017 First Quarter Results
www.prnewswire.com - May 5 at 8:53 AM |
 | Oncolytics reports 1Q loss
marketbeat.com - May 5 at 7:18 AM |
| Oncolytics Biotech announces registration pathway and clinical development plan - Seeking Alpha
seekingalpha.com - April 14 at 6:40 PM |
 | Biopharmaceutical Market Scope Rising With Escalating Health Concerns - IndustryARC
globenewswire.com - March 28 at 6:48 PM |
| BRIEF-Shanghai Shyndec Pharma's unit fined by food and drug authorities - Reuters
www.reuters.com - March 4 at 12:03 AM |
| Global Oncolytic Virus Landscape 2017: Key Players, Key Technologies, Projects, Business Deals and Private and ... - GlobeNewswire (press release)
globenewswire.com - January 31 at 5:48 AM |
| Oncolytics Biotech® Inc. Appoints Dr. Matt Coffey to the Role of President and CEO - PR Newswire (press release)
www.prnewswire.com - January 21 at 7:40 AM |
| BRIEF-Oncolytics Biotech names Matt Coffey CEO
www.reuters.com - January 19 at 11:41 PM |
| Targovax announces appointment of Erik Digman Wiklund as CFO ... - GlobeNewswire (press release)
globenewswire.com - January 5 at 5:53 AM |
Oncolytics Biotech (TSE:ONC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Oncolytics Biotech (TSE ONC) Stock Chart for Sunday, April, 22, 2018
Loading chart…
